Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Graft vs. Host Disease (GvHD) Clear all
Withdrawn Phase 3 Interventional

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

NCT03066466
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
Atorvastatin, Methotrexate, Tacrolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

NCT03613727
View directory record Official record
Conditions
Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
Interventions
Intravenous (IV) and oral Vitamin C
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 77 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2Phase 3 Interventional

Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

NCT00035880
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
ABX-CBL
Drug
Lead sponsor
Abgenix
Industry
Eligibility
1 Year and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 11:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

NCT06874283
View directory record Official record
Conditions
Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
Interventions
Eye exam
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD

NCT02066051
View directory record Official record
Conditions
GVHD, Ocular Rosacea, Dry Eye Syndrome
Interventions
IPL, Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

NCT02867384
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Obinutuzumab, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

NCT02806947
View directory record Official record
Conditions
Acute GVHD
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648
View directory record Official record
Conditions
Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ Topical Gel 1%, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

NCT00431873
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Kansas City, Missouri • New York, New York • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Not applicable Interventional Results available

Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease

NCT02203578
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
romidepsin, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers

NCT00399308
View directory record Official record
Conditions
Leg Ulcer, Varicose Ulcer
Interventions
Celaderm (Frozen Cultured Epidermal Allograft), Control (compression bandaging)
Device
Lead sponsor
Shire
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Tamarac, Florida • Niles, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

NCT00075023
View directory record Official record
Conditions
Graft-versus-Host Disease, Stomatitis
Interventions
Thalidomide Gel, Placebo Gel
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

NCT02491359
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Carfilzomib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Buffalo, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 13, 2026, 11:37 PM EDT
Active, not recruiting Phase 4 Interventional

Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain

NCT06897280
View directory record Official record
Conditions
Chronic, Intractable Back Pain and/or Leg Pain
Interventions
SCS Device Program Setting
Device
Lead sponsor
Nevro Corp
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02683525
View directory record Official record
Conditions
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

NCT01149668
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Lafayette, Indiana • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 13, 2026, 11:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

NCT00967096
View directory record Official record
Conditions
Malignancy, Bone Marrow Transplantation
Interventions
Rifaximin
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

NCT00001623
View directory record Official record
Conditions
Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplant
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 13, 2026, 11:37 PM EDT
Completed No phase listed Observational Results available

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT02130557
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions
Bosutinib, Imatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
65
States / cities
Anaheim, California • Atlanta, Georgia • Honolulu, Hawaii + 40 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

NCT02652130
View directory record Official record
Conditions
Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
Interventions
Remestemcel-L
Biological
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 13, 2026, 11:37 PM EDT